Anti-CD25 chimeric monoclonal antibody (Shanghai Zhangjiang Biotechnology)

重组抗CD25人鼠嵌合单抗（上海张江生物）

Report date: 2022/07/15 15:58:56

Base Information

Drug NameAnti-CD25 chimeric monoclonal antibody (Shanghai Zhangjiang Biotechnology)
Drug Alias Name注射用重组抗CD25人鼠嵌合单克隆抗体（上海张江）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsRejection of organ transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantation

Other Information

ATC CodeN/A
Related LinksN/A